Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Funding Deals: Generation Bio Raises $110m For Non-Viral Gene Therapies

Executive Summary

Recent venture funding for emerging biopharma companies, including CF PharmTech, Codagenix, Empirico, Epirium, Generation, Kyverna, NorthSea, VectivBio, Rig and Tarsus. 

You may also be interested in...



Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine

Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance

The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.

New Cash Moves NorthSea Up In NASH

With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel